Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials?
Zackova D, Klamova H, Dusek L, Muzik J, Polakova KM, Moravcova J, Jurcek T, Dvorakova D, Racil Z, Pospisil Z, Oltova A, Michalova K, Brezinova J, Razga F, Doubek M, Cetkovsky P, Trneny M, Mayer J. Zackova D, et al. Among authors: dvorakova d. Am J Hematol. 2011 Mar;86(3):318-21. doi: 10.1002/ajh.21942. Epub 2011 Feb 15. Am J Hematol. 2011. PMID: 21328429 Free article. No abstract available.
The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population.
Racil Z, Razga F, Buresova L, Jurcek T, Dvorakova D, Zackova D, Timilsina S, Cetkovsky P, Mayer J. Racil Z, et al. Among authors: dvorakova d. Am J Hematol. 2010 Jul;85(7):525-8. doi: 10.1002/ajh.21722. Am J Hematol. 2010. PMID: 20575042 Free PMC article. No abstract available.
The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia.
Razga F, Racil Z, Machova Polakova K, Buresova L, Klamova H, Zackova D, Dvorakova D, Polivkova V, Cetkovsky P, Mayer J. Razga F, et al. Among authors: dvorakova d. Int J Hematol. 2011 Sep;94(3):303-306. doi: 10.1007/s12185-011-0924-6. Epub 2011 Sep 8. Int J Hematol. 2011. PMID: 21901397 No abstract available.
Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.
Zackova D, Klamova H, Muzik J, Cmunt E, Racil Z, Machova Polakova K, Dvorakova D, Jurcek T, Razga F, Cetkovsky P, Dusek L, Mayer J. Zackova D, et al. Among authors: dvorakova d. Leuk Lymphoma. 2013 Oct;54(10):2310-3. doi: 10.3109/10428194.2013.772173. Epub 2013 Feb 28. Leuk Lymphoma. 2013. PMID: 23373966 No abstract available.
Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
Doubek M, Palasek I, Pospisil Z, Borsky M, Klabusay M, Brychtova Y, Jurcek T, Jeziskova I, Krejci M, Dvorakova D, Mayer J. Doubek M, et al. Among authors: dvorakova d. Exp Hematol. 2009 Jun;37(6):659-72. doi: 10.1016/j.exphem.2009.03.004. Exp Hematol. 2009. PMID: 19463768 Free article.
Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: detection of the T315I mutation in bone marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood.
Razga F, Jurcek T, Jeziskova I, Zackova D, Dvorakova D, Borsky M, Mayer J, Racil Z. Razga F, et al. Among authors: dvorakova d. Mol Diagn Ther. 2012 Jun 1;16(3):163-6. doi: 10.2165/11632420-000000000-00000. Mol Diagn Ther. 2012. PMID: 22489663
126 results